Therapy Area topics
Cardiovascular
Go or no go? Valuable drugs set for FDA decisions
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
Diabetes
Akero continues to pull ahead of Nash rivals
Biopsy data set up efruxifermin as a strong contender in the race to find an effective Nash treatment.
Digital Health
Philips sells the household goods and could spend on tech instead
Digital health is a core focus for Philips. Might more acquisitions be on the way?
Oncology
Healthineers makes its ambition plain with $16.4bn Varian buy
Suddenly 2020’s medtech M&A landscape looks very different.
Respiratory
The scramble to reinvent the ventilator
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
Various
Go or no go? Valuable drugs set for FDA decisions
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
